SPEAKERS

Elizabeth Baca

Mary E. Edgerton, M.D.

Associate Professor, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center

Mary E. Edgerton was born in Austin, Texas and was raised in the Rio Grande Valley. She received a B.S. in Physics with Highest Honors from the University of Texas at Austin. Following this, she was a Marshall Scholar to the United Kingdom where she received a Ph.D. in Biophysics from the University of East Anglia. She completed postdoctoral studies at the Unviersity of California at San Francisco and at the State university of New York at Stony Brook, and then worked for nine years for Exxon and then Mobil Oil Company in their research laboratories. She left the research laboratoires to attend medical school, and obtained her MD. from Medical College of Pennsylvania in Philadelphia. She completed her pathology residency and surgical pathology fellowship at the Hospital of the University of Pennsylvania. She is board certified in Anatomic and Clinical Pathology and was an Assistant Professor of Pathology at Vanderbilt University and an Associate Professor in the Division of Anatomic Pathology at the Moffitt Cancer Center before coming to MD Anderson, where she is currently an Associate Professor with tenure.

Elizabeth Baca

Amylynne Santiago Volker

President and Founder, Nicholas Volker One in a Billion Foundation.

Amylynne was born in Chicago Illinois, and raised in rural South central and Madison, WI where she currently resides. She serves as the Founder and President of the Nicholas Volker One In A Billion Foundation a 501(c)(3) nonprofit organization with a mission to Inspire the world to improve the quality of life
for those with undiagnosed and rare disease by advancing the practice of personalized and genomic medicine. Amylynne is the mother of five children including her son Nic who is widely celebrated as the first person in the world saved by DNA sequencing and described as one of the faces of the Human Genome Project by Francis Collins.
As Nic battled a life threatening, mysterious illness over the course of several years, it was in part Amylynne’s unrelenting pursuit of answers and tireless advocacy for her son that led to the historic sequencing of his DNA & ultimately the bone marrow transplant that saved his life. A Pulitzer Prize Winning Series “One in a Billion: A boy’s life; a medical mystery” and a book published by Simon and Schuster “One in a Billion the Story of Nic Volker and the Dawn of
Genomic Medicine” were both written largely based on Amylynne’s Caringbridge Journal which chronicled Nic’s fight to live and their medical and diagnostic odyssey. Amylynne now fights for patients and families with undiagnosed, rare and or life threatening illnesses and is well known in the community for her healthcare Advocacy and Activism.
Amylynne started healthcare initiatives in WI that have become law, lobbies regularly on behalf of patients with special needs for improved health care policy at the state and federal level and as a Rare Disease Legislative Advocate in Washington D.C. Amylynne has met with the Speaker of the House Paul Ryan on multiple occasions and other members of Congress in a quest for additional funding for the NIH and garner support for the recently passed 21st Century Cures Legislation. Amylynne has also privately met with the Director of the National Institutes of Health to advocate for targeted research and soon will be launching a Natural History Study and Registry for pediatric patients with XIAP and NLRC4 @www.oneinabillionic.com.

Elizabeth Baca

Matthew McManus, MD, PhD.

President and CEO, Asuragen., Inc.

Dr. McManus joined Asuragen in August 2014 bringing more than 20 years of clinical diagnostic leadership experience. Matt was most recently CEO and President of PrimeraDx, Inc., a molecular diagnostics company acquired by Qiagen. He has held leadership positions in a number of other companies, including Head of Cleveland Clinic Laboratories, COO of the Pathology and Laboratory Medicine Institute at the Cleveland Clinic, and a variety of positions at Novartis, McKinsey & Co., and Procter & Gamble. Dr. McManus received his MD and PhD from the University of Pennsylvania, MBA from Boston College and BA from the College of the Holy Cross.

Elizabeth Baca

Ross Higgins, MBA.

Director of Laboratory Operations, OneOme

Don Skifter, Ph.D., MBA, Vice President of Business Development, joined the OneOme team in May of 2016. Don has spent the past 15 years of his career in various commercial roles within genetic technology and services sectors including roles most recently at the Broad Institute where he helped to formally launch Broad Genomic Services and at Complete Genomics, Sequenom, and Invitrogen/Life Technologies/Thermo Fisher prior to that. Don received his PhD in pharmacology and neuroscience from the University of Nebraska Medical Center and his MBA from the University of Nebraska Omaha.

Elizabeth Baca

Nick Lench

Chief Operating Officer – Congenica Ltd.

Nick was previously Director of the NE Thames Regional Genetics Service at Great Ormond Street Hospital for Children, with responsibility for the strategic and operational management of a genetics service that provides DNA diagnostic testing to a population of approximately 4.5M people. Nick is an honorary Reader at the UCL Institute of Child Health, and has over 25 years of research experience in human molecular genetics. He was awarded a personal chair in Medical Genetics at Cardiff University in 2005 and is a founding CEO of London Genetics Ltd and Programme Director at Oxagen Ltd.

Elizabeth Baca

PHILIP BEALES

Medical Director – Congenica Ltd.

Phil is a consultant physician and Professor of Medical and Molecular Genetics at the UCL Institute of Child Health (ICH), an NIHR Senior Investigator, an Honorary Consultant in Clinical Genetics at Great Ormond Street Hospital (GOSH) and the lead on Personalised Medicine for UCL. He is an internationally recognized expert in the genetics and pathogenesis of ciliopathies and pioneering use of next generation sequencing in mapping disease genes in this area.

Elizabeth Baca

WALTER (Buzz) STEWART, PhD, MPH

Chief Research Officer – Sutter Health

Buzz Stewart, Chief Research Officer, joined Sutter Health in July 2012. He oversees research organized around Digital Health and Advanced Analytics, Precision Care & Medicine, Clinical Trials, and Rapid Health System Learning. Buzz has transformed the research model at Sutter to be translation focused and strategic in supporting Sutter as a Learning Health Care System. His personal interests span the unique role of health system research in transforming care through predictive analytics, population health management, and digital health.

Prior to Sutter, Buzz founded the Geisinger Center for Health Research (2003-2012), a research and development unit that participated in Geisinger’s decade long strategy to transform the delivery of health care. Previously, he was a faculty member at the Johns Hopkins Bloomberg School of Public Health (1983-1995), was Vice President of Research and Development at AdvancePCS (1998-2002) and founded several successful start-ups.

He has published more than 400 peer-reviewed articles (h-index>105) and book chapters after receiving his PhD in Epidemiology from Johns Hopkins University, his MPH from UCLA, and his BS in Psychobiology from University of California, Riverside.

Elizabeth Baca

Jerry Conway

Vice President of Payer Relations & Reimbursement, Foundation Medicine Inc.

Jerry Conway, Vice President of Payer Relations & Reimbursement, joined Foundation Medicine Inc. in May 2012 with over 22 years of sales and executive management experience in the routine clinical and esoteric laboratory marketplaces working first in physician sales and marketing, then later with national and regional payers on contracting, education and utilization management initiatives involving laboratory services. His experience includes payer contracting and reimbursement in a wide range of business environments including Fortune 500 and start-up companies. In 2011, Jerry joined Metamark Genetics Inc., a national provider of cancer prognostic tests and services, as Vice President of Reimbursement & Payer Contracting. At Metamark, Jerry was responsible for payer strategy development for several assays in the pre-launch phase. In 1997, Jerry joined Genzyme Genetics, a national provider of genetic health services, to develop business relationships and contracts with regional and national payers based in the Northeastern United States. In 2001, he was promoted to the role of Director of National Accounts with Genzyme Genetics and was responsible for business development and contracts with national and cross-regional payers. In 2004, Jerry was promoted to Vice President of Managed Care where he oversaw a staff of 11 regional and national account directors who were focused on payer account management, contracting, pull through, education and care management programming. With a particular focus on reimbursement for routine and novel genetic tests and services in the reproductive and oncology markets at Genzyme Genetics, Jerry has a demonstrated track record of increased revenue and profitability. Under his leadership in payer contracting and reimbursement over 14 years, Jerry helped to favorably position the company for a recent $975 million acquisition by Laboratory Corporation of America® Holdings on December 1, 2010.

Elizabeth Baca

Valerie A. Schneider, Ph.D.

Staff Scientist, National Center for Biotechnology Information

Dr. Schneider received her Ph.D. from Harvard University in 2001 and did her post-doctoral training at the University of Pennsylvania School of Medicine (2001-2007). Since 2008, she has been a Staff Scientist at the National Center for Biotechnology Information (NCBI). NCBI is a member of the GRC (Genome Reference Consortium), the group responsible for updating the human, mouse, zebrafish and chicken reference genome assemblies. Dr. Schneider leads the team of curators and developers at NCBI responsible for the analysis and data management of the GRC assemblies, as well as the development of tools for assembly QA and curation. Her team is also responsible for the development of tools and infrastructure used for genome visualization and analysis, including the NCBI genome browser suite, and the NCBI Genome Remapping Service. As the head of the Sequence View program at NCBI, she oversees the development of a variety of web-based and stand-alone resources that help users take advantage of the wealth of genomic data that is now available in the public sphere.

Elizabeth Baca

Katlin McKelvie Backfield, JD.

Founding Partner, Backfield PLLC

Katlin McKelvie Backfield advises companies on issues related to the regulation of pharmaceuticals. With over 15 years of experience in the area of pharmaceutical regulatory law, including more than 10 years at the Food and Drug Administration, she uses her extensive expertise to help companies navigate the pre- and post-approval stages of drug development. Katlin served as Associate Chief Counsel for D ugs with the Office of Chief Counsel at FDA for nine
years. She was a regulatory counsel in the Office of Prescription Drug Promotion in the Center for Drug Evaluation and Research at FDA from 2006 to 2008.

Prior to joining FDA, Katlin was an associate at Hogan Lovells, LLP, and a law clerk for the Honorable Douglas P. Woodlock of the U.S. District Court for the District of Massachusetts. She graduated cum laude from Georgetown University Law Center and received her undergraduate degree from Davidson College.
Katlin is a member of the Food and Drug Law Institute’s Academic Programs Committee. She has developed and conducted training workshops for employees across FDA and for the Food and Drug Law Institute’s Introduction to Drug Law course.

Elizabeth Baca

Anna D. Barker, Ph.D.

Co-Director, Complex Adaptive Systems (CAS), Director, National Biomarker Development Alliance (NBDA)

As Co-Director of CAS, Dr. Barker designs and implements new research models specifically directed toward addressing major problems in biomedical research and biomedicine. CAS at ASU serves as an organizing construct to understand and solve multi-dimensional problems in the biomedical and health sciences. These multi-sector networks are the foundation for the development of new research models that leverage convergent knowledge and novel funding approaches to understand and improve the diagnosis and treatment of complex diseases.

Prior to joining ASU, Dr. Barker served several years as the Deputy Director and Deputy Director for Strategic Scientific Initiatives for the NCI, National Institutes of Health (NIH). At the NCI Dr. Barker developed and led or co-led a number of trans-disciplinary programs including: Nanotechnology Alliance for Cancer, The Cancer Genome Atlas (TCGA); and the Clinical Proteomics Technologies Initiative. Dr. Barker also led a multi-year effort to plan and implement a new trans-disciplinary research construct to enable the convergence of the physical sciences (physics, mathematics, physical chemistry and engineering) with cancer biology. Under her leadership, the NCI developed major initiatives in bio specimen science and bioinformatics. She was founding co-chair of the NCI-FDA Interagency Task Force (IOTF) and founding co-chair of the Cancer Steering Committee of the FNIH Biomarkers Consortium (FNIH-BC). She also oversaw the NCI’s international cancer research programs, including pilot programs in Latin America and China. Prior to joining the NCI, she co-founded and served as CEO of a public biotechnology company preceded by several years at Battelle Memorial Institute where she served as vice president of the Institute’s biomedical research sector.

Her research interests include complex adaptive systems and applications in biomedical research; disease, biomarker(s) discovery and development; advanced clinical trial models; and experimental therapeutics and free-radical biochemistry in cancer etiology and treatment. Dr. Barker received her B.S. from Morehead State University; and her M.A. and Ph.D. at the Ohio State University, where she trained in immunology and microbiology.

Elizabeth Baca

Elizabeth Baca, MD.

Senior Health Advisor in the Governor’s Office of Planning and Research

Dr. Elizabeth Baca is passionate about innovations to foster total health and well-being. She currently serves as the Senior Health Advisor in the Governor’s Office of Planning and Research (OPR). She is engaged in innovation in the public sector to foster health through multiple projects including healthy planning, big data, and public-private partnerships. For healthy planning she works across sectors to foster collaboration, elevate the connection between health and the built environment, and leads the effort to incorporate health considerations into the planning process to build healthy, resilient communities. A significant part of her work is aligning win-wins for projects that offer co-benefits, particularly with respect to climate mitigation and adaptation efforts. For big data, she is working on projects to link data sets to the planning process. Additionally, she serves as a lead for the Governor’s Initiative to Advance Precision Medicine. Through her role in OPR, she is an advisor for the USGBC Building Health Initiative and FS6, a new Food System Accelerator.

Previously, she served on the General Pediatric Faculty at Stanford Medical School and directed the Community Pediatric and Child Advocacy Rotation. In addition to teaching medical students and residents about the social, economic, and environmental factors that affect health, Dr. Baca was the lead faculty mentor on several projects to increase access to healthy foods, reduce environmental triggers of asthma, increase physical activity opportunities, and improve the built environment.
Dr. Baca studied health p

licy at Universidad Simon Bolivar in Venezuela. She completed her Masters in Public Administration at Harvard Kennedy School of Government and her Doctorate of Medicine at Harvard Medical School. Dr. Baca completed her pediatric residency in the Pediatric Leadership for the Underserved (PLUS) program at University of California, San Francisco.

Jennifer Pearce, MPA

Jennifer Pearce, MPA

Founder, Plain Language Health

A passionate advocate for patient engagement through understanding, Jennifer brings 18 years of experience collaborating with researchers, providers and patients to advance health literacy.

In 2012 she founded Plain Language Health, a consultancy that specializes in co-producing care and research content patients can easily understand and act on. Previously, Jennifer led Sutter Health’s award-winning health literacy initiatives, as well as patient experience research within the 24-hospital system. Prior to joining Sutter, she led national patient engagement efforts for five NIH-funded genetic studies of autoimmune disease at the University of California San Francisco.

Jennifer’s work has been recognized by the Institute for Healthcare Advancement and the Center for Plain Language in Washington, D.C., earning ClearMark Awards of Distinction in 2012 and 2013. She currently serves on the Center’s board of directors.

Jennifer earned her MPA in Healthcare Administration from California State University East Bay and her BA from the University of California, San Diego.

Riley Bove, MD

Riley Bove, MD

UCSF Multiple Sclerosis Center, and an Assistant Professor in the UCSF Department of Neurology

Riley Bove, MD (co-Investigator) is a board-certified neurologist practicing at the UCSF Multiple Sclerosis Center, and an Assistant Professor in the UCSF Department of Neurology. She obtained her undergraduate degree from Harvard College, her MD from Harvard Medical School, and completed her neurology training and multiple sclerosis (MS) research fellowship in the joint Massachusetts General Hospital and Brigham and Women’s Hospitals Partners program.

Her research interest in MS is to identify new strategies and targets to promote neurological recovery, including through emerging technologies and hormonal modulation. Since joining UCSF, she has been promoting the advancement of precision medicine in MS care by expanding the accessibility of the MS BioScreen (neurology.ucsf.edu/research/ms-bioscreen). New developments include an open access patient-facing Open MS BioScreen, as well as a clinically actionable tool that sits directly on the electronic medical record at Sutter (MS-SHARE).

Her work has been funded by the National Institutes of Health, the National MS Society, the California Initiative to Advance Precision Medicine, and the Conrad Hilton Foundation, among others.

Mark Trusheim

Zakiuddin Ahmed, MBBS

Project Director, Kind Saud University

Dr. Zakiuddin Ahmed is a visionary strategist, healthcare entrepreneur & a physician leader who specializes in developing socially beneficial. sustainable, scalable and innovative solutions in Healthcare through information technology

Areas of Interest/Expertise: eHealth / mHealth, Digital Healthcare Marketing, Healthcare Quality, Healthcare Leadership, eLearning, Ethics, Strategic Planning & Patient Centric Health Advocacy

Mark Trusheim

Mark Trusheim

Strategic Director, NEWDIGS, MIT Center for Biomedical Innovation

Mark Trusheim is Strategic Director, NEWDIGS at the MIT Center for Biomedical Innovation and a Visiting Scientist at the MIT Sloan School of Management. He is the Founder of Co-Bio Consulting, LLC and has been a Special Government Employee for the FDA’s Office of the Commissioner.

Mark’s research focuses on the economics of biomedical innovation, especially precision medicine, adaptive pathways, platform trials and digital health advances. His work emphasizes using quantitative modeling in multi-stakeholder processes to inform public policy, corporate strategy, and product development.

Prior to MIT, his career spanned big data and simulations at Kenan Systems, marketing at Searle Pharmaceuticals, eHealth as Vice President of Monsanto Health Solutions, genomics as President of Cereon Genomics, molecular diagnostics as CEO of start-up Cantata Laboratories and policy as the President of the Massachusetts Biotechnology Council.

He holds degrees in Chemistry from Stanford University and Management (Finance and IT) from MIT.

Maurice Treacy, PhD MBA

Maurice Treacy, PhD MBA

Strategic Relationships, Co-Founder Genomics Medicine Ireland

Maurice has over 20 years’ executive leadership experience in the biotech, pharma and life-science sectors, with extensive experience in innovative scientific research and drug development.He is former CEO and co-founder of HiberGen, a startup genomics-based drug development company and was a Director of Life Sciences at Science Foundation Ireland (SFI) and CEO of the National Institute for Bioprocess Research & Training (NIBRT). Most recently, he was Venture Partner with ARCH Venture Partners and with the Growcorp Group, an Irish VC firm. Maurice holds a PhD in Pharmacology from UCD and a MBA from Northeastern University. He is an Adjunct Professor at the UCD Smurfit Business School. He is a co-inventor on over 80 USA patents applications.

Robert Loberg, Ph.D.

Robert Loberg, Ph.D.

Director Medical Sciences, Head of Clinical Biomarkers and Diagnostics, Amgen

Robert Loberg, PhD, Director Medical Sciences, is the Head of Clinical Biomarkers and Diagnostics at Amgen and is responsible for discovery, development and execution of biomarker and diagnostic strategies to support the Amgen portfolio across all therapeutic areas. Dr. Loberg leads a team of biomarker scientists and computational biologists in pursuit of biomarker and diagnostic driven drug development efforts. Dr. Loberg joined Amgen in 2009 in the Oncology Biomarker group within Medical Sciences. He served as the Biomarker Lead for multiple oncology programs and was responsible for biomarker discovery and development activities of clinical candidates from pre-First in Human studies through clinical development. In addition, he led an active lab-based research group charged with technology evaluation and biomarker discovery/implementation to support the biomarker needs of a growing pipeline. In 2013, Robert assumed the role of Director Medical Sciences / Therapeutic Area Lead, Clinical Biomarkers – Oncology and was responsible for management of discovery, development and execution of biomarker strategies across the Oncology portfolio.

Dr. Loberg received his B.A. degree in biology from Baylor University and Ph.D. from The University of Michigan. He completed his post-doctoral training in a prostate cancer biology laboratory. Following his post-doctoral fellowship he joined the faculty at The University of Michigan as an Assistant Professor in Internal Medicine and Urology where he continued his research in prostate cancer. Dr. Loberg has authored more than 50 peer reviewed scientific publications and is involved in a number of scientific consortia advancing translational medicine in drug development and medical research.

Daniel H. Mathalon, Ph.D., M.D.

Daniel H. Mathalon, Ph.D., M.D.

Professor of Psychiatry, UCSF

Daniel Mathalon, Ph.D., M.D. is a Professor in the Departments of Psychiatry at the University of California, San Francisco. He directs the Early Psychosis Program at UCSF and the Brain Imaging and EEG Laboratory located at the San Francisco VA Medical Center, where he also serves as Chief of General Psychiatric Outpatient Services. Dr. Mathalon received a B.A. in Psychology from U.C. Berkeley, a Ph.D. in Psychology from Indiana University, and an M.D. from Stanford University. He completed his psychiatric residency training and a research fellowship in Psychophysiology at Stanford University. Following this training, he joined the Psychiatry faculty at Yale University, and after 8 years, he moved to his current position at UCSF. Dr. Mathalon uses EEG and MRI based measures to study brain dysfunction in neuropsychiatric disorders, particularly schizophrenia. A major focus of his work has been to identify neurophysiological biomarkers of risk for schizophrenia among individuals exhibiting putatively prodromal symptoms. Current efforts are focused on examining abnormalities in neural plasticity as a basis for gray matter loss and neurocognitive impairments in schizophrenia.

Henry Hess, PhD

Henry Hess, PhD

Director, Corporate Innovation Strategy at Merck KGaA, Darmstadt, Germany

Henry Hess, PhD, is Director at the Corporate Innovation Center at Merck KGaA, Germany. Prior to that he spend over 20 years in BioPharma R&D at various companies, including Biogen, Pfizer and Roche. His tenure with Merck started in 2008. His expertise centers in immunology and pharmacology and spans the entire value chain of R&D.
At Merck, Dr. Hess forged several teams to become the foundation for the then at Merck nascent therapeutic area of Autoimmunity and Inflammatory Diseases. He is a member of the Senior Management and TA leadership team, responsible for target concept evaluation, portfolio management and lead discovery strategy assessment. Dr. Hess was chairman of the Systemic Lupus Erythematosus (SLE) disease task force responsible for defining, communicating and implementing Merck/EMD’s SLE drug discovery and development strategy. Prior to Merck, Dr. Hess worked for Parke-Davis Pharmaceutical Research/IRJ, Paris, France, where was the head of the newly established Immunopharmacology group, a role he subsequently held at several companies, including Biogen Idec Inc. and Pfizer Global Research & Development, Fresnes Laboratories, France. Dr. Hess is a graduate of the University of Mainz, Germany, where he received his degree in Biology and Immunology in 1996 following a sabbatical year in Michael Longenecker’s group at Biomira in Edmonton, Canada. He carried out his research as a postdoctoral fellow at Roche Milano Ricerche, Milan, Italy.

Christopher A. Longhurst, MD, MS

Christopher A. Longhurst, MD, MS

Chief Information Officer, UC San Diego Health
Clinical Professor of Biomedical Informatics and Pediatrics, UC San Diego School of Medicine

As Chief Information Officer, Dr. Longhurst is responsible for all operations and strategic planning for information and communications technology across the multiple hospitals, clinics, and professional schools which encompass UC San Diego Health. Dr. Longhurst is also a Clinical Professor of Biomedical Informatics and Pediatrics at UC San Diego School of Medicine, and continues to see patients. He previously served as Chief Medical Information Officer for Stanford Children’s Health and Clinical Professor at the Stanford University School of Medicine, where he helped lead the organization through the implementation of a comprehensive electronic medical record (EMR) for over a decade. This work culminated in HIMSS stage 7 awards for both Lucile Packard Children’s Hospital and 167 network practices in Stanford Children’s Health.

Dr. Longhurst has published dozens of scientific articles in peer-reviewed journals on how technology and data can improve patient care and outcomes and was elected as a fellow in the prestigious American College of Medical Informatics, among other distinctions. He is a board-certified pediatrician and clinical informaticist, and founded Stanford’s fellowship in clinical informatics, first in the nation to receive accreditation. Described as a pragmatic academician, Dr. Longhurst, serves as an advisor to several companies and speaks internationally on a wide gamut of healthcare IT topics

Nigam H. Shah, MBBS, PhD

Nigam H. Shah, MBBS, PhD

Associate Professor of Medicine (Biomedical Informatics Research) and Bilogical Data Science, Stanford University

Bryce Olson is the Marketing Director for Intel’s Health and Life Sciences group. One of the areas he focuses on is bringing technology and science together in the exciting area of genomics and precision medicine with a powerful message on how this saves lives. Genomic sequencing and precision medicine gave him a life he didn’t think he’d get to live.
Bryce is inspired by connecting the advances in life sciences into clinical settings and helping patients understand these new opportunities. He is a sought after keynote speaker both locally and nationally, and his story has been covered by both local and national media. Bryce also started FACTS (‘Fighting Advanced Cancer Through Songs’), a movement that uses the power of music to build awareness for a new way to fight cancer and bring molecular testing and precision medicine to other advanced cancer patients. In 2017, Bryce wrote and co-produced a rock-n-roll album with proceeds going towards the FACTS movement, that brought together a variety of Portland, Oregon based musicians and singers including Jenny Conlee from the Decemberists, Martha Davis from the Motels, Pete Krebs, and Michelle DeCourcy – all four who are also cancer survivors.

Bryce Olson

Bryce Olson

Global Marketing Director, Health and Life Science, Intel Corporation

Bryce Olson is the Marketing Director for Intel’s Health and Life Sciences group. One of the areas he focuses on is bringing technology and science together in the exciting area of genomics and precision medicine with a powerful message on how this saves lives. Genomic sequencing and precision medicine gave him a life he didn’t think he’d get to live.
Bryce is inspired by connecting the advances in life sciences into clinical settings and helping patients understand these new opportunities. He is a sought after keynote speaker both locally and nationally, and his story has been covered by both local and national media. Bryce also started FACTS (‘Fighting Advanced Cancer Through Songs’), a movement that uses the power of music to build awareness for a new way to fight cancer and bring molecular testing and precision medicine to other advanced cancer patients. In 2017, Bryce wrote and co-produced a rock-n-roll album with proceeds going towards the FACTS movement, that brought together a variety of Portland, Oregon based musicians and singers including Jenny Conlee from the Decemberists, Martha Davis from the Motels, Pete Krebs, and Michelle DeCourcy – all four who are also cancer survivors.

Frederick J. Meyers, MD, MACP

Frederick J. Meyers, MD, MACP

Associate Dean for Precision Medicine & Professor of Internal Medicine / hematology-oncology at UC Davis School of Medicine

Dr. Frederick Meyers is the Associate Dean for Precision Medicine and professor of internal medicine / hematology-oncology at UC Davis School of Medicine. He has served UC Davis as chief of hematology-oncology, chair of the Department of Internal Medicine and vice dean of the School of Medicine.

Dr. Meyers has a long-standing interest in cancer biology, with a focus on advanced and metastatic malignancies. His earliest publications in the molecular oncology of urologic cancers emphasized clinical trials with laboratory correlative studies. He recognized the inherent ethical conflict between early-phase cancer clinical trials and the need to deliver palliative and end-of-life care. Many of his early grants and publications highlighted this apparent paradox that he resolved by developing a model of simultaneous or concurrent care. The systems-based improvement of cancer-care delivery integrated cancer therapy and palliative care at the same time, rather than sequentially, and changed the paradigm of the care of patients with both advanced malignancy and nonmalignant illnesses, successfully introducing palliative care earlier in the trajectory of illness. This forms the basis for his ongoing commitment to quality of care improvement, and he has long been an advocate for integrating QI into health sciences education.

Dr. Meyers is strongly committed to the career development of junior scholars, MD and PhD, pre-and postdoctoral. He directs the Research Education and Career Development core of the UC Davis NIH-funded Clinical Translational Science Center (CTSC). His commitment is reflected in his service as principal investigator of several training grants including the CTSC Mentored Clinical Research Training Program, a California stem cell research training grant and a grant from HHMI Integrating Medicine into Basic Sciences. He is PI of the UC Davis NIH Common Fund Broadening Experiences in Scientific Training (BEST) award. His current focus is leading and integrating precision medicine across all of the colleges and schools at UC Davis and the communities it serves.

Don Hardison

Don Hardison

President & CEO, Biotheranostics, Inc.

Don Hardison has more than 30 years of executive leadership experience in both emerging and Fortune 500 companies, including roles as CEO and COO, as well as a board member. Most recently, Don served as president, CEO, and director of Good Start Genetics, Inc. He also served in a similar capacity at EXACT Sciences Corp., where he was actively involved in taking the company public and was primarily responsible for a novel multi-million dollar strategic partnership with Laboratory Corporation of America (LabCorp). He has extensive experience in diagnostic laboratory management, sales, marketing, strategy, operations and broad reimbursement expertise. Don also has held multiple senior leadership positions at companies such as LabCorp, Quest Diagnostics, and SmithKline Beecham Corp., where he built a strong track record in strategy development, team building, and market planning and execution.

Iya Khalil, PhD

Iya Khalil, PhD

Chief Commercial Officer and Co-Founder, GNS Healthcare

Dr. Khalil is a technology entrepreneur and physicist with a vision of transforming medicine into a discipline that is quantitative, predictive, and patient-centric via big data analytic approaches. She co-founded two big data companies, Via Science and GNS Healthcare, and is the co-inventor of the proprietary computational engine that underpins both entities. She trained in theoretical physics at Cornell University, and has more than 11 years of experience in “big data” analytics for healthcare, medicine, and the life sciences.

She has led several key foundational collaborations with providers, pharmaceutical companies, foundations, and government agencies. Dr. Khalil’s expertise spans applications in drug discovery, drug development all the way to treatment algorithms that can be applied at the point of care. She is a frequent speaker at industry events and conferences, has appeared in several industry journals, published several articles in the field, and was recognized by President Obama at a White House dinner as a leading entrepreneur in genomic medicine. More recently, she was named to the PharmaVOICE 100 list of the most inspiring people in the life sciences industry. She was recognized for her ability to build bridges across the life science and healthcare industries, bringing people together to harness the power of predictive modeling to change the lives of patients.

Patricia Carrigan, Ph.D.

Patricia Carrigan, Ph.D.

Global Head of Translational Assay Technology, Bayer AG

Patricia Carrigan, Ph.D. has over 20 years of experience in the life science industry focusing the majority of her time on Biomarker discovery/translational research, and the development of Companion Diagnostics. Currently, she is the Global Head of Translational Assay Technology for Bayer AG focusing her team efforts on bringing cutting edge technologies/ biomarker strategies to Oncology, Women’s health, and Cardiovascular Phase I/II clinical trials. In addition her team also oversees the technical and regulatory development strategies for Bayer’s RX-CDx co-development programs. Prior to Bayer, Patricia built a high performing team as a Senior Manager of Assay Development at Roche-Ventana where her team was responsible for developing robust prototype Immunohistochemical and In Situ Hybridization assays. Some of the key programs that she managed which are now at the forefront of Immuno-oncology and Precision Medicine include PDL1, ROS, ALK, and BRAFV600E IHC Companion Diagnostics.

In her earlier years Patricia worked at the International Genomics Consortium and the Molecular Profiling Institute. At IGC, she was the Director of Assay Development and manager of the Biospecimen Core Repository which was the main supplier of tumor material for the Cancer Genome Atlas Pilot Program. While at the Molecular Profiling Institute which is now Caris, she helped develop and validate the Target Now panel, which is now referred to Caris’s Moleculer Intelligence Panel. She holds a Ph.D. in Biochemistry and Molecular Biology from the Mayo Clinic College of Medicine, Rochester Minnesota.

Fred H. Gage, Ph.D.

Fred H. Gage, Ph.D.

Adler Professor, Laboratory of Genetics, The Salk Institute
Adjunct Professor, UCSD

Fred H. Gage, Ph.D., a Professor in the Laboratory of Genetics, joined The Salk Institute in 1995. He received his Ph.D. in 1976 from The Johns Hopkins University. Dr. Gage’s work concentrates on the adult central nervous system and unexpected plasticity and adaptability to environmental stimulation that remains throughout the life of all mammals. In addition, he models human neurological and psychiatric disease in vitro using human stem cells. Finally his lab studies the genomic mosaicism that exists in the brain as a result of mobile elements that are active during neurogenesis.

Prior to joining Salk, Dr. Gage was a Professor of Neuroscience at the University of California, San Diego. He is a Fellow of the American Association for the Advancement of Science, a Member of the National Academy of Sciences and the Institute of Medicine, and American Philosophical Society, a foreign member of the European Molecular Biology Organization and a Member of the American Academy of Arts and Sciences.

Dr. Gage has served as President of the Society for Neuroscience in 2002, and past President for the International Society for Stem Cell Research 2012.

Randy Burkholder

Randy Burkholder

Vice President, Policy & Research, Pharmaceutical Research and Manufacturers of America

Randy Burkholder is Vice President of Policy and Research at the Pharmaceutical Research and Manufacturers of America. Mr. Burkholder leads PhRMA work on policy solutions for supporting continued biopharmaceutical innovation and high-quality, patient-centered health care, including payment and delivery reform, quality measurement, appropriate use and patient adherence, evidence-based medicine and health technology assessment, value of innovation and personalized medicine. Mr. Burkholder represents PhRMA at federal agencies and advisory bodies including the Medicare Evidence Development and Coverage Advisory Committee, CMS’ Technical Expert Panel on oncology, and the Federal Coordinating Council for Comparative Effectiveness Research. He also is a former member of the Board of Directors of the Personalized Medicine Coalition and serves on the Steering Committee of the Partnership to Improve Patient Care and the advisory committee for the Turning the Tide Against Cancer initiative.

Mr. Burkholder has over 20 years experience in health care policy, advocacy and communications in the medical technology and pharmaceutical industries.

Prior to joining PhRMA, Mr. Burkholder was Associate Vice President for Public Affairs at AdvaMed, the leading association of the medical device and diagnostics industries.

Thomas A Bock, MD, MBA

Thomas A Bock, MD, MBA

Chief Executive Officer of HeritX

Dr. Thomas Bock is the Chief Executive Officer of HeritX, a global R&D organization focused on stopping inherited gene mutations from turning into cancer, starting with BRCA cancers. HeritX’s pipeline of targeted pre-cancer interventions (PCIs) includes enhancers of genomic stability as well as pre-cancer vaccines.

Dr. Bock believes that precision medicine can make its greatest impact through pre-disease intervention, the only way to achieve a world without disease.  Dr. Bock’s broad experience in cancer and ultra-orphan diseases spans academic medical research, the US National Institutes of Health and the biopharmaceutical industry.

Following his research on stem cell and genetic therapies at the National Human Genome Research Institute as well as his oncology medical practice and research at international cancer centers, Dr. Bock served in European and global leadership roles at Amgen, Novartis Oncology, and Celgene.  Prior to founding HeritX, he served as Senior Vice President of Global Medical Affairs and member of the executive management team of Alexion, rated #2 in innovation across all industries (Forbes).

Dr. Bock has built entrepreneurial teams and organizations driving the global medical programs of more than 15 therapies and product launches, including life-saving breakthroughs such as the first targeted cancer therapy, the first immune-modulatory cancer therapy and the first complement inhibitor for autoimmunity.

Dr. Bock’s focus on alliances across academia, industry, and the patient community has propelled medical progress for patients with multiple diseases, and is a pillar of HeritX’s accelerated R&D platform for rapidly turning research ideas into to available therapies. Dr. Bock has received numerous scientific and professional awards.

Robert Sebra, Ph.D.

Robert Sebra, Ph.D.

Associate Professor, Department of Genetics and Genomic Sciences, Icahn Institute of Genetics and Multiscale Biology, Mount Sinai

Robert Sebra, Ph.D. leads Technology Development at the Icahn Institute of Genetics and Multiscale Biology and Sema4 Genomics and Associate Professor in the Department of Genetics and Genomic Sciences. He pioneers technology adoption, and research and development to create high-throughput diagnostics and innovative molecular biology techniques to generate high-resolution data applying bulk and single cell sequencing technologies for clinically driven applications. Dr. Sebra has published more than 50 papers in top tier journals, including Science, Cell, Nature, NEJM, and Cancer Discovery, and his work has led to multiple issued patents.

Since establishing a team at Icahn School of Medicine at Mount Sinai, Dr. Sebra has applied WGS and targeted genomics approach toward a better understanding of genomic variation for higher resolution human disease diagnostics in cancer and inherited disease, alongside infectious disease surveillance using both long- and short-read sequencing techniques. Prior to his work at Sinai, Dr. Sebra was involved in research and development contributing to single molecule real-time long read sequencing technology and applications at Pacific Biosciences after receiving his Ph.D. in Chemical and Biological Engineering at University of Colorado, Boulder.

David Spetzler, Ph.D., MBA

David Spetzler, Ph.D., MBA

Chief Scientific Officer, Caris Life Sciences

Dr. David Spetzler joined Caris Life Sciences in August of 2009, and has held several management positions with increasing responsibilities during his tenure. He currently serves as President and Chief Scientific Officer and provides executive leadership for the company’s service lines, Caris Molecular Intelligence® and ADAPT Biotargeting System™.

Under his leadership, the R&D team is focused on the development of clinical assays to aid in the creation of precision medicine strategies for individual cancer patients, as well as noninvasive technologies to identify and predict early stage cancer. Much of work is focused on the development of the ADAPT Biotargeting System™, a groundbreaking and proprietary method of profiling macro-molecular complexes in their native form in a highly multiplexed format. The innovative technology is the result of the convergence of Caris’ deep expertise in Next-Generation Sequencing, exosome biology, bioinformatics and broad-based molecular profiling.

Prior to his position at Caris, Dr. Spetzler was a member of the research faculty at Arizona State University where he developed multiplexed nanotechnologies for single molecule detection of nucleic acid and protein targets. He also developed novel methods of using DNA to create biological computers to solve NP-complete optimization problems, and built a novel optical detection system capable of measuring single molecule protein conformational changes with microsecond time resolution. At Arizona State University Dr. Spetzler earned an MS from the School of Mathematical and Statistical Science in Computational Bioscience, a Ph.D. in Molecular Cellular Biology and an MBA. Dr. Spetzler is an adjunct faculty member of the molecular cellular biology program at Arizona State University, a scientific and commercial reviewer for SBIR/STTR grants for NSF, co-authored more than twenty patents, and has published numerous research articles.

Eric Glassy, M.D.,FCAP

Eric Glassy, M.D.,FCAP,

Director of Pathology, Providence Little Company of Mary Medical Center.

Dr. Glassy is a community pathologist in Southern California and director of pathology at Providence Little Company of Mary Medical Center, San Pedro. He is a member of Affiliated Pathologists Medical Group, a 40 person independent pathology group covering 15 hospitals and laboratories in California, Portland and Phoenix. Dr. Glassy has won a number of pathology awards, including the Distinguished Service Award and Excellence in Education Award from the College of American Pathologists (CAP). He has chaired hospital and CAP national committees. He served as chairman of the Hematology and Clinical Microscopy Resource, Publications, Digital Pathology and Curriculum Committees. He is a past Board Member of the CAP Foundation and a graduate of the Engaged Leadership Academy. He is president of the Digital Pathology Association. He edited, wrote and illustrated several pathology color atlases and developed software programs for pathology reporting, outreach, and practice management. He holds a green belt in Six Sigma. He is a trustee of the American Board of Pathology as well as a board of governor of the College of American Pathologists.

Bruce Quinn, M.D.,Ph.D.

Bruce Quinn, M.D.,Ph.D.,

Principal, Bruce Quinn Associates LLC

Bruce Quinn, M.D., Ph.D., partners with the leadership of innovative companies to craft successful business strategies in digital health and life sciences. With a nationwide client base, Dr. Quinn has worked successfully with both large and small companies in overcoming hurdles to commercialization through negotiation, understanding insightful ways to use the existing healthcare system to advantage. Dr. Quinn has helped stakeholders change federal policies in multiple domains and is an expert on the Medicare system.

Dr. Quinn travels nationwide to speak on health reform issues and publishes actively, including a widely read blog, “Discoveries in Health Policy,” which updates readers on federal policy changes in precision medicine as well as other health topics. In 2016, he published “Digital Health: Impact on Genomics,” a white paper describing digital genomics as a unique industry.

Before establishing Bruce Quinn Associates LLC, Dr. Quinn was a physician executive in the health and life sciences division of Accenture, working with the pharma, biotech and genomics industries. He also served as the regional Medicare medical director for the California Part B program, where he had authority for final coverage decisions on approximately 15 percent of the U.S. Medicare program and he spearheaded innovative approaches to coverage of new technologies. For eight years, he worked full time for Washington-based policy and lobbying groups. Dr. Quinn holds an MD-PhD from Stanford University and an MBA from the Kellogg School of Management.

Karen Nelson, Ph.D.

Karen Nelson, Ph.D.,

President, J. Craig Venter Institute (JCVI)

Dr. Karen E. Nelson is the President of the J. Craig Venter Institute (JCVI) and head of the Microbiome group at Human Longevity Inc., in La Jolla California. Prior to being appointed President, she held a number of other positions at the JCVI, including Director of JCVI’s Rockville Campus, and Director of Human Microbiology and Metagenomics in the Department of Human Genomic Medicine at the JCVI. Originally from Jamaica, Dr. Nelson received her undergraduate degree from the University of the West Indies, and her Ph.D. from Cornell University. She has authored or co-authored over 170 peer reviewed publications, edited three books, and is currently Editor-in-Chief of the journal Microbial Ecology. She also serves on the Editorial Boards of BMC Genomics, GigaScience, and the Central European Journal of Biology. She is also a member of the National Academy of Sciences Board of Life Sciences, a Fellow of the American Academy of Microbiology, an Honorary Professor at the University of the West Indies and a Helmholtz International Fellow. Dr. Nelson has extensive experience in microbial ecology, microbial genomics, microbial physiology and metagenomics. Dr. Nelson has led several genomic and metagenomic efforts, and led the first human metagenomics study that was published in 2006. Additional ongoing studies in her group include metagenomic approaches to study the ecology of the gastrointestinal tract of humans and animals, studies on the relationship between the microbiome and various human and animal disease conditions, reference genome sequencing and analysis primarily for the human body, and other -omics studies.

Jeanette McCarthy, MPH, PhD

Jeanette McCarthy, MPH, PhD

Founder, Precision Medicine Advisors

Jeanette McCarthy, MPH, PhD is a UC Berkeley trained genetic epidemiologist and spent the early part of her career in industry at Millennium Pharmaceuticals before transitioning to academia. She currently holds adjunct faculty positions at UCSF and Duke University. Her previous research had focused on the genetic underpinnings of complex diseases, both infectious and chronic. More recently, she has become a leading educator in the field of genomic and precision medicine. Jeanette helped launch the first consumer-facing magazine in this field, Genome, and served as Editor-in-Chief from 2014-2016. She developed the first MOOC on precision medicine, offered through Coursera, and teaches at UCSF and UC Berkeley Extension as well. Jeanette is coauthor of the book, Precision Medicine: A Guide to Genomics in Clinical Practice (from McGraw Hill Education).

Li Liu, MD

Li Liu, MD

Assistant Professor of Biomedical Informatics and Director of the Bioinformatics Core Facility, Arizona State University

Dr. Liu is an assistant professor of Biomedical Informatics and the director of the Bioinformatics Core Facility at Arizona State University. She holds an M.D. degree in Medicine and an M.S. degree in Information System. As a trained clinician and a bioinformatics researcher, she fully appreciates the critical roles genomic medicine and bioinformatics play in advancing precision medicine. By integrating genomic, phylogenetic, population genetic, statistical and machine-learning techniques, Dr. Liu and her research team investigate clinical and molecular signatures of human diseases, and develop novel computational methods to discover biomarkers for early diagnosis and accurate prediction of therapeutic responses for individual patients. Before joining ASU, Dr. Liu helped build and directed the bioinformatics core facility at University of Florida.

Elizabeth Mansfield, Ph.D.

Head of Regulatory Strategy , GRAIL

Elizabeth Mansfield is the Head of Regulatory Strategy at GRAIL. Prior to GRAIL, Liz was Deputy Office Director for Personalized Medicine and Director of the Personalized Medicine Staff in the Office of In Vitro Diagnostic Devices (OIVD) in the Center for Devices at the FDA, where she developed a program to address companion and novel diagnostic devices. She also previously served as a Senior Policy Analyst in OIVD, managing policy and scientific issues, and served in other positions at the FDA including Scientific Reviewer and Genetics Expert. Previously at Affymetrix, Liz was the Director of Regulatory Affairs (2004-2006). She holds a PhD from Johns Hopkins University and completed further postdoctoral training at the National Cancer Institute (NCI) and the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS).

Milan Vukicevic, Ph.D.

Milan Vukicevic, Ph.D.

Assistant Professor, University of Belgrade, Faculty of Organizational Sciences

Milan Vukicevic is an Assistant Professor at the University of Belgrade, Faculty of Organizational Sciences. He worked as a Visiting Researcher at the Data Analysis and Biomedical Analytics (DABI) Center at Temple University (2014-2015). His research interests encompass design and development of predictive algorithms and their application in health care predictive modeling. Specific areas of his technical interest include sparse predictive models, fusion of domain knowledge and data-driven methods ,parameter optimization and feature selection, predictive analytics on heterogeneous data sources and meta-learning. His work was published in number of international conferences, journals and book chapters. Milan had several invited talks on bioinformatics and healthcare predictive analytics. He is a PC member of
The Fifth IEEE International Conference on Healthcare Informatics (ICHI 2017), Park City, Utah, USA and 2017 IEEE International Conference on Big Data December 11-14, 2017, Boston, MA, USA

Adrijana Kekic, PharmD, BCACP, CTLC.

Program Director Outpatient Pharmacy Education, Mayo Clinic

Adrijana Kekic is a Program Director of Education, Outpatient Pharmacy at Mayo Clinic in Phoenix, Arizona. She is active in clinical care, research and lecturing and has been involved in development of pharmacogenomics services and education. She is a licensed pharmacist in Arizona.
Dr. Kekic earned the Doctor of Pharmacy degree from Midwestern University College of Pharmacy in Glendale, Arizona. She is board certified ambulatory care pharmacist through Board Pharmacy Specialties (BPS) and a member of BPS Ambulatory Care Committee. She holds a certification in Pharmacogenomics from University of Florida College of Pharmacy and is pursuing a Genomic Medicine certification from Stanford University.
Adrijana has served as an adjunct faculty at Midwestern University College of Pharmacy and an instructor, preceptor and residency preceptor at Mayo School of Medical Science. She is involved with several pharmacogenomics research projects and studies in palliative care, transplant care, anesthesia and cardiology. She sits on Pharmacogenomics Task Force at Mayo Clinic.
With two decades of clinical experience and expertise in medication therapy management , Adrijana continues to advance pharmacy practice and pharmacy leadership. She is a founder of a networking platform dedicated to high impact professional women in healthcare. She collaborated with Arizona State University (ASU), Harvard Medical School, Thunderbird School of International Business and University of Arizona.

Jerry SH Lee, Ph.D.

Jerry SH Lee, Ph.D.

Deputy Director, Center for Strategic Scientific Initiatives, Office of the Director, National Cancer Institute, National Institutes of Health

Dr. Lee serves as a Health Sciences Director within the National Cancer Institute’s Office of the Director’s Center for Strategic Scientific Initiatives where he provides leadership and oversight in planning, developing, and implementing rapid strategic technology initiatives that keep the Institute ahead of the scientific curve of potential new exciting areas and discoveries.

Since its inception in 2003, the Center has supported more than 2,000 trans-disciplinary projects through programs such as the Innovation Molecular Analysis Technologies (IMAT), NCI Alliance for Nanotechnology in Cancer, The Cancer Genome Atlas (TCGA), Clinical Proteomic Tumor Analysis Consortium (CPTAC), Physical Sciences-Oncology Centers (PS-OC), Provocative Questions (PQ), and Cancer Target Discovery and Development (CTD2) network. These exploratory initiatives focus on the integration of advanced technologies, trans-disciplinary approaches, infrastructures, and standards, to accelerate the creation of publicly available, broadly accessible, multi-dimensional data, knowledge, and tools to empower the entire cancer research continuum for patient benefit. In 2016, Dr. Lee was assigned to Office of the Vice President to serve as the Deputy Director for Cancer Research and Technology for the White House Cancer Moonshot Task Force. A few key efforts he helped coordinate include the Applied Proteogenomics OrganizationaL Learning and Outcomes Network (APOLLO), international collaborations to share molecular characterization datasets, the Blood Profiling Atlas in Cancer pilot, as well as co-chairing an interagency group focused on cancer data and technology policy issues.

Dr. Lee earned his bachelor`s degree in biomedical engineering and Ph.D. in chemical and biomolecular engineering from Johns Hopkins University, where he continues research as an adjunct associate professor. He is a member of the Innovation Policy Forum of the National Academies Board on Science, Technology, and Economic Policy, the Foundation for the NIH’s Biomarkers’ Consortium Cancer Steering Committee, the Health and Environmental Sciences Institute’s Board of Trustees, and the editorial board of Convergence Science Physical Oncology journal.

Razelle Kurzrock, MD

Razelle Kurzrock, MD

Senior Deputy Center Director, Clinical Science, Director, Center for Personalized Cancer Therapy, Director, Clinical Trials Office, Team Leaders, Experimental Therapeutics, UCSD Moores Cancer Center, Chief, Division of Hematology and Oncology , UC San Diego School of Medicine

Dr. Razelle Kurzrock is known for developing the largest Phase 1 clinical trials department in the nation/world while at the University of Texas M.D. Anderson Cancer Center. A central theme of that program was the personalized medicine strategy, embodied in a protocol called PREDICT for Profile-related Evidence Determining Individualized Cancer Therapy. This approach utilized advanced molecular technologies to match patients with targeted cancer treatment that is more likely to work for their individual tumors.

At Moores Cancer Center, Dr. Kurzrock’s charge is broad, including not just growing and innovating the center’s clinical trials program, but also heading its newly established Center for Personalized Cancer Therapy. This center focuses on precision medicine trials, using the most innovative genomically-targeted drugs and/or agents that arm the immune system. As a physician-scientist, Dr. Kurzrock brings extraordinary expertise and experience in clinical research, business operations, regulatory operations, financial and budget planning, and administrative oversight, in addition to her world-recognized work in translational science. Dr. Kurzrock is also Chief of the Division of Hematology and Oncology in the UC San Diego School of Medicine. Dr. Kurzrock received her MD degree from the University of Toronto and has over 600 peer-reviewed publications and a uniquely strong record of competitive grant funding within the setting of Phase I program building.

Dr. Kurzrock also has a strong history of building outstanding education/training programs. At University of Texas MD Anderson Cancer Center, she founded and directed the MS/PhD program (degree granting) in Human Biology and Patient-Based Research, as well as the Fellowship in Investigational Cancer Therapeutics. At UCSD Moores Cancer, she founded and directs the Fellowship in Personalized Cancer Therapy.

Dr. Kurzrock has four children and lives with her husband, Dr. Philip Cohen, a dermatologist, in San Diego, CA.

Mara Aspinall, MBA

Mara Aspinall, MBA,

President & CEO – Health Catalysts

Aspinall is a healthcare industry leader and pioneer with a commitment to active civic involvement. Aspinall is the President and CEO of Health Catalysts, an investment and advisory firm dedicated to the growth of new healthcare companies. Aspinall is also Executive Chairman of GenePeeks, a computational genomics company leading a paradigm shift in genetic testing and personalized medicine. GenePeeks’ proprietary technology can identify the risk of passing on more than 1100 monogenic diseases to progeny through data mining the maternal and paternal genomes with pre-conception testing.
Aspinall is a member of the Board of Directors of Allscripts (NASDAQ:MDRX), Abcam plc (AIM:ABC), 3Scan, Blue Cross Blue Shield Arizona and Castle Biosciences.
Aspinall is the former President and CEO of Ventana Medical Systems, a division of the Roche Group, worldwide leader in development and commercialization of tissue-based cancer diagnostics. At Ventana, with her world class team, she led the company to new market success, more than two dozen major instrument and assay launches and global leadership in companion diagnostics.
Previously, Aspinall spent 12 years with Genzyme as President of Genzyme Genetics and Genzyme Pharmaceuticals. Genzyme Genetics was sold to LabCorp for $1 billion in 2010. Aspinall was also Founder and CEO of On-Q-ity, a start-up diagnostic company dedicated to circulating tumor cells.
With a passion for education about the importance of diagnostics, Aspinall co-founded the International School of Biomedical Diagnostics at Arizona State University and Dublin City University, the first school ever dedicated entirely to Diagnostics as an independent discipline. The School awarded their first Master degrees in the summer of 2015 and will graduate Master’s students this year.
Aspinall has spearheaded initiatives to educate payers and policymakers on genomics and personalized medicine. She served as an active member of the Health and Human Services Secretary’s Advisory Council on Genetics, Health & Society (SACGHS) in both the Obama and Bush administrations. Aspinall was also a Trustee of the Dana Farber Cancer Institute for 11 years, where she chaired the Trustee Science Committee.
Within Arizona, Aspinall is the Chair of the Arizona Biosciences Board, a CEO group focused on increasing opportunities in the state for technology companies. She is also a Board member of the Southern Arizona Leadership Council and Sun Corridor.

Aspinall is a frequent international speaker and author on healthcare related issues. She was named Arizona Biosciences Leader of the Year in 2016 by the Arizona Biotechnology Association and one of “100 Most Inspiring People in Life Sciences” by PharmaVOICE magazine.
Mara started her business career at the strategic consulting firm Bain & Company. She holds an MBA from Harvard Business School and a BA in International Relations from Tufts University.

Kate Sasser, Ph.D.

Kate Sasser, Ph.D.

Vice President, Head of Oncology Translational Research, Janssen, Pharmaceutical Companies of Johnson and Johnson

Associate Professor Kaylene Simpson Heads the Victorian Centre for Functional Genomics (VCFG) at Peter MacCallum Cancer Centre. The VCFG enables researchers Australia-wide to perform unbiased gene discovery using high throughput gene targeting approaches such as CRISPR/cas9 and RNA interference, quantitative Reverse Phase Protein Arrays, boutique compound screening and high content imaging. She leads a highly experienced team who actively engage with researchers to help drive their research projects to fruition. Associate Professor Simpson is a molecular cell biologist who specialised in breast cancer invasion and metastasis while a postdoctoral fellow at Harvard Medical School. She has a wealth of experience in assay development, data interpretation and analysis and overall guidance in the area of functional genomics. She is a founding Board member and the current president of the Society of Biomolecular Imaging and Informatics (SBI2).

Nick van Terheyden, MD

Nick van Terheyden, MD

Chief Medical Officer for NTT DATA Services Healthcare & Life Sciences

Dr. Nick brings a distinctive blend of medical practitioner and business strategist, both national and international, to the realm of healthcare technology. A graduate of the Royal Free Hospital School of Medicine, University of London, Dr. Nick is a pioneering creator in the evolution of healthcare technology. After several years as a medical practitioner in London and Australia, he joined an international who’s who in healthcare, academia and business, in the development of the first electronic medical record in the early 1990’s and later, as a business leader in one of the first speech recognition Internet companies.
His rare combination of patience, creativity, skill and intrinsic business ethics has led him to a diverse career in healthcare with some of the most prestigious hospitals, consulting firms, and technology companies. He is a member of the HIMSS mHealth Committee where he pays attention not just to processes and systems, but to people. His ability to speak in terms people can actually understand makes him a sought-out speaker on the practical and futuristic use of healthcare technology and how it can cost-effectively improve patient care.
In addition to writing and lecturing on futuristic trends in healthcare technology, his advice and counsel is sought by hospitals, physicians and other allied healthcare professionals — all of whom are trying to figure out how to integrate and use technology to make the healthcare system work from the perspectives of quality and financial success.

Chris Grilli, PharmD.

Chris Grilli, PharmD.

Manager of Outpatient Pharmacy, Mayo Clinic

Chris received his Doctorate of Pharmacy from Creighton University College of Pharmacy. In addition he is Board Certified in Ambulatory Care Pharmacy through the Board of Pharmacy Specialties. Currently he oversees outpatient pharmacy operations for Mayo Clinic Arizona. He helped found Mayo Clinic Arizona’s Ambulatory Medication Therapy Management Program as well as a Pharmacogenomics program specialty. He is also a founding member of Mayo Clinic’s enterprise wide Pharmacogenomic Round Table.
Chris is a dedicated educator, precepting as often as possible. In collaboration with ASU he is actively researching process improvement and healthcare delivery workflows within Mayo Clinic’s multidisciplinary practice. In addition Chris is tasked with overseeing all pharmacy operations for our Ambulatory Infusion Center located on our Scottsdale campus. He also has developed a full service compounding operation so that patients can have their medications individualized.
With over a decade of experience in pharmacy leadership and practice Chris has been tasked with brining pharmacogenomics from the bench to the bedside.

Michael Misialek, MD

Michael Misialek, MD.

Associate Chair, Pathology, Newton-Wellesley Hospital

Dr. Misialek currently serves as Associate Chair of Pathology at Newton-Wellesley Hospital, Newton, MA. He is the Medical Director of the Vernon Cancer Center, Chemistry Laboratory and Point of Care Testing. Holding an academic appointment at Tufts University School of Medicine, he regularly instructs medical students and pathology residents. Dr. Misialek is a strong advocate for pathology and is very active in the College of American Pathologists (CAP), serving on the Personalized Healthcare Committee, the Council for Membership and Professional Development, the political action committee PathPAC and the CAP Foundation. He is an inspector with the CAP and has conducted numerous hospital laboratory inspections. He served on the Clinical and Laboratory Standards Institute (CLSI) Document Development Committee on “Reporting Critical, Life-Threatening, or Life-Altering Lab Results” and currently serves on the CLSI Document Development Committee on “Specimen Handling for Molecular Methods”.
He received his MD from the University of Massachusetts, did an internship in internal medicine at Boston Medical Center and completed his residency in anatomic and clinical pathology at the University of Massachusetts Medical Center. He did a fellowship in surgical pathology at the University of Florida and is board certified in Anatomic and Clinical Pathology.

Kaylene Simpson, Ph.D.

Kaylene Simpson, Ph.D.

Associate Professor & Head Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre

Associate Professor Kaylene Simpson Heads the Victorian Centre for Functional Genomics (VCFG) at Peter MacCallum Cancer Centre. The VCFG enables researchers Australia-wide to perform unbiased gene discovery using high throughput gene targeting approaches such as CRISPR/cas9 and RNA interference, quantitative Reverse Phase Protein Arrays, boutique compound screening and high content imaging. She leads a highly experienced team who actively engage with researchers to help drive their research projects to fruition. Associate Professor Simpson is a molecular cell biologist who specialised in breast cancer invasion and metastasis while a postdoctoral fellow at Harvard Medical School. She has a wealth of experience in assay development, data interpretation and analysis and overall guidance in the area of functional genomics. She is a founding Board member and the current president of the Society of Biomolecular Imaging and Informatics (SBI2).

Thomas P. Conrads, Ph.D.

Thomas P. Conrads, Ph.D.

Thomas P. Conrads, PhD, Associate Director of Scientific Technologies, Inova Schar Cancer Institute

 

Thomas P. Conrads, PhD, a nationally-recognized translational cancer researcher, serves as the Associate Director of Scientific Technologies in the Inova Schar Cancer Institute. He also serves as the Chief Scientific Officer of the Department of Defense Gynecologic Cancer Center of Excellence and is leading the discovery proteomics efforts in the Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) program in the US Federal Cancer Moonshot that is working to obtain detailed proteogenomic profiles on 8000 cancer patients. Dr. Conrads’ scientific career has been spent developing new technologies in chemistry and biology and applying cutting-edge applications and workflows in genomics and proteomics for systems biology and cancer biomarker discovery and validation in tissues, proximal fluids and serum/plasma. The overarching goals of his research are toward identification of genomic, proteomic and small molecule biomarkers and surrogates for enhanced cancer patient management through improved early detection, patient stratification, and monitoring for therapeutic efficacy, outcome and recurrence.

Simon Lovestone, Ph.D.

Simon Lovestone, Ph.D.

Professor of Translational Science – University of Oxford Department of Psychiatry

Simon Lovestone is Professor of Translational Neuroscience at Oxford University and has research interests in the regulation of tau phosphorylation, in the search for genetic and other biomarkers of Alzheimer’s disease and building on these, in drug discovery and experimental medicine. Underpinning all these studies is the use of informatics – clinical informatics, bioinformatics and the challenges of extracting value from very large variable datasets. He is also a practicing Old Age Psychiatrist specialising in dementia detection, diagnosis and management. The lab group’s work is described here http://www.psych.ox.ac.uk/research/dementia-research-group and the ARUK Oxford Drug Development Institute led by Lovestone and Bountra is here http://oxford-ddi.alzheimersresearchuk.org/

Jun Wang, Ph.D.

Jun Wang, Ph.D.

Founder and CEO of iCarbonX

Jun Wang is the Founder and CEO of iCarbonX. He is also Board Member of the BGI (previously known as the Beijing Genomics Institute). He co-founded BGI in the 1999, which is now widely recognized as one of world’s premier research facilities committed to excellence in genome sciences. Dr. Wang also holds a position as an Ole Rømer professor at the University of Copenhagen.

He has authored 400+ peer-reviewed original papers – of which 100+ are published in Cell, Nature (including Nature series), N Engl J Med., and Science (26 as cover story). He has been recognized with an award from His Royal Highness Prince Foundation, Nature’s 10 – the year in Science (2012); “Highly Cited Researchers (2013/2014/2015)” “The Hottest Scientific Researchers” (by Thomson Reuters), “Rebels, leaders, innovators for the next 25 years” (by CNBC), “Fortune’s 40 under 40” from Fortune Magazine (2013), Lundbeck Talent Price, Outstanding Science and Technology Achievement from the Chinese Academy of Sciences, Outstanding Technical Talent, ZhouGuangZhao Award, TanJiaZeng Life Science Innovation Award, Top 10 Scientific Achievements In China, Major Award from Shenzhen Municipal Government, and Prize for Important Innovation and Contribution from Chinese Academy of Sciences.

His research focuses on genomics and related bioinformatics analysis of complex diseases and agricultural crops, with the goal of developing applications using the genomic information.

Dr. Wang also managed to have three round fund-raising (about 1B$) at BGI, and acquired a US public company: Complete Genomics. Oct 27th 2015, Dr. Wang founded a new institute/company, iCarbonX, aiming to establish a health-related big Omics data platform, to develop artificial intelligence engine to interpret and mine the data as well as to enable every individual to better manage their health and defeat diseases.

Larry Gold, Ph.D.

Larry Gold, Ph.D.

Chairman and Founder of Somalogic, Founder of NeXstar and Synergen

Dr. Larry Gold is the Founder and Chairman of the board, and Past CEO of SomaLogic. Prior to SomaLogic, he also founded NeXagen, Inc., which later became NeXstar Pharmaceuticals, Inc. In 1999, NeXstar merged with Gilead Sciences, Inc. to form a global organization committed to the discovery, development and commercialization of novel products that treat infectious diseases. Before forming NeXagen, he also co-founded and served as co-director of research at Synergen, Inc., a biotechnology company later acquired by Amgen, Inc.
Since 1970, Dr. Gold has been a professor at the University of Colorado at Boulder. While at the university, he served as the chairman of the Molecular, Cellular and Developmental Biology Department from 1988 to 1992. Dr. Gold has received many citations including the CU Distinguished Lectureship Award, the National Institutes of Health Merit Award, the Career Development Award, and the Chiron Prize for Biotechnology.

Deepak Asudani, MD, MPH

Deepak Asudani, MD, MPH

Associate Clinical Professor of Medicine at University of California, San Diego

Dr. Asudani is an Associate Clinical Professor of Medicine at University of California, San Diego. He graduated with Bachelors in Medicine and Surgery from Rajasthan University, India and went on to complete Internal Medicine residency from New York Medical College, New York. With strong interest in public policy, global health and population health he completed Masters in Public Health from University of Massachusetts, Amherst. An alumni of Harvard Kennedy School of Government Executive education, he is also actively engaged in various leadership roles. He serves as the Medical Director for Hospital Medicine International Patients’ Program and is Chair, Outreach and Clinical Integration. He has been actively engaged with the Practice Management Committee and Public Policy Committee of the Society of Hospital Medicine. This has allowed him to work closely with national thought leaders in public policy development and advocacy. He has a strong interest in applied genomics with particular focus on pharmacogenomics. He believes that modern day genomic sequencing technology delivers a more focused understanding of an individual’s genetic configuration, and in this context – a better pixelated understanding of personalized diagnostics and therapeutics. He will be a regular contributor to the Journal of Precision Medicine’s Clinical Perspective section.

Peter Hoehn

Peter Hoehn

Co Dx Commercial Strategy Leader, Janssen Pharmaceuticals

Peter Hoehn is the Co Dx, Commercial Strategy Leader within the Global Commercial Strategy Organization of Janssen Pharmaceuticals, responsible for leading strategic marketing and market access for companion and complementary diagnostics (Co Dx) across all Therapeutic Areas. Peter and his team lead the assessment of potential diagnostic projects and commercial evaluation of prospective diagnostic partners, and lead commercial strategy development and launch readiness for Janssen Co Dx projects in development. In this role, Peter also has responsibility for Co Dx market access strategy, including development of clinical utility plans, pricing and reimbursement strategies, and Co Dx policy.

Peter received a BA in Government and Economics from the College of William and Mary, and a JD from New York University. He started his career as a corporate lawyer, and entered the pharmaceutical industry as an attorney for Bristol Myers Squibb. After a short time as a lawyer at BMS, Peter moved in to various strategy, marketing and sales management roles.

Peter joined Johnson & Johnson in 2003 in the Pharmaceuticals Group Strategic Marketing organization as Global Commercial Leader for Reminyl, and in 2005 was promoted to Global Marketing Leader – Neurology, where he had global commercial responsibility for in-line neurology products as well as products in late stage of development. In 2008 Peter joined the Ortho Clinical Diagnostics (OCD) organization as Global Marketing Leader and was promoted to Vice President for WW Marketing and Strategic Marketing in 2010. In this role, Peter and his team set overall marketing strategies and plans for the world-wide Clin Labs diagnostics business, defined and managed the pipeline of new products and identified and assessed new growth opportunities. In 2012 Peter moved from OCD to the Janssen Diagnostics group.

Peter currently represents Janssen Diagnostics on the AdvaMed Dx Board and is Co-Chair of the Bio NJ Committee on Diagnostics and Precision Medicine.

Mark Boguski, MD

Mark Boguski, MD

Chief Medical Officer of Inspirata, Inc.

Dr. Mark Boguski is the Chief Medical Officer of Inspirata, Inc. and founded the Precision Medicine Network in 2014. He is member of the U.S. National Academy of Medicine and a Fellow of both the College of American Pathologists and the American College of Medical Informatics. Dr. Boguski has served on the faculties of the U.S. National Institutes of Health, the Johns Hopkins University School of Medicine and Harvard Medical School and as an executive in the biotechnology and pharmaceutical industries. He is a former Vice President and Global Head of Genome and Protein Sciences at Novartis and a graduate of the Medical Scientist Training Program at Washington University in St. Louis.

Hannah Mamuszka

Hannah Mamuszka

Founder and CEO of Alva10

Hannah Mamuszka is the Founder and CEO of Alva10, a company focused on driving up the value of diagnostics in healthcare. Ms Mamuszka founded Alva10 after having spent almost 20 years in the Cambridge, MA biotech community, with extensive experience in both drug and diagnostic development, validation, and commercialization. Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda).
Diagnostics are the key to Precision Medicine, but they need to be valued in the healthcare market in order to be successful. For years, diagnostics have been stuck in a downward cycle of value, with poor reimbursement leading to lack of investment, and lack of investment leading to sub-optimal clinical validation, leading back to poor reimbursement. Alva10 is changing that, bringing diagnostics to the forefront of Precision Medicine by partnering with payers and diagnostics companies using a proprietary algorithm to determine economic impact of diagnostics and create a new value based healthcare model.

Alan Sachs, MD, Ph.D.

Alan Sachs, MD, Ph.D.

Chief Scientific Officer for Thermo Fisher Scientific

Dr. Sachs leads efforts to maximize growth through investments in R&D that position the company to help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. He served as the Chief Scientific Officer for Life Technologies and Life Sciences Solutions Group within Thermo Fisher between 2012 and 2015. Prior to this role, Dr. Sachs was the Vice President of Exploratory and Translational Sciences at Merck Research Laboratories. During his ten years at Merck, he built and directed the global RNA Therapeutics Department, led the Rosetta Inpharmatics group, and led the Department of Molecular Profiling. Before joining Merck, Dr. Sachs was an Associate Professor of Molecular and Cell Biology at the University of California at Berkeley, and a Whitehead Institute Fellow at the Whitehead Institute in Cambridge, MA. Dr. Sachs graduated from Cornell University with a B.A. in Biochemistry, and at Stanford Medical School received his Ph.D. with Roger Kornberg in Cell Biology, his M.D., and performed post-doctoral research with Ron Davis. Dr. Sachs is on the Board of Directors for Imago BioSciences and Advisory Board for Bakar Fellows at University of California, Berkeley.

Dr. Simon Kos, MBBS, BSc, MBA

Dr. Simon Kos, MBBS, BSc, MBA

Chief Medical Officer, Worldwide Health, Microsoft

Dr. Simon Kos joined Microsoft in 2010 to bring health domain expertise to the health team. He brings insight and experience from over 17 years working in the healthcare and Health IT industries. As the doctor on Microsoft’s Worldwide Health team, he is responsible for clinical strategy and industry engagement. He raises awareness of the Microsoft brand, technologies and partner community, and works to find clinical relevance for Microsoft products.
Prior to coming to Microsoft, Dr. Kos worked with global health IT companies Cerner and InterSystems as they implemented some of the largest e-Health initiatives in the Asia-Pacific region. His responsibilities included product design and localisation, clinical engagement, industry thought leadership and team management. Before his career in health IT Dr. Kos practiced as a doctor at NSWHealth, Australia for several years with a focus on critical care.
Dr. Kos has an MBBS and BSc(Med) from UNSW, and an MBA with a major in change management from AGSM. He is passionate about improving healthcare through technology.

Gary Siuzdak, Ph.D.

Gary Siuzdak, Ph.D.

Professor & Senior Director, The Scripps Research Institute

Gary Siuzdak is Professor and Director of the Scripps Center for Metabolomics at The Scripps Research Institute. He is an affiliate scientist at the Lawrence Berkeley National Lab and has served as Vice President of the American Society for Mass Spectrometry. His research includes developing novel technologies for metabolomics, imaging and system biology. He has over 200 peer-reviewed publications and two books including the “The Expanding Role of Mass Spectrometry in Biotechnology”.

Mary Maxon

Mary Maxon

Biosciences Area Principal Deputy at Lawrence Berkeley National Laboratory

Mary Maxon is the Biosciences Area Principal Deputy at Lawrence Berkeley National Laboratory, where she is responsible for developing strategies for the use of biosciences to address national-scale challenges in energy and environment. She has extensive experience in both the public and private sectors, having served as the Assistant Director for Biological Research at the White House Office of Science and Technology Policy (OSTP) in the Executive Office of the President, where she developed the National Bioeconomy Blueprint, Director of the Marine Microbiology Program at the Gordon and Betty Moore Foundation, and in executive and management roles at Cytokinetics and Microbia, Inc. Maxon received her Ph.D. from the University of California, Berkeley and performed postdoctoral research in biochemistry and genetics at the University of California, San Francisco.

Hans Erik Henriksen

Hans Erik Henriksen

CEO of Healthcare DENMARK

Hans Erik Henriksen is CEO of Healthcare DENMARK. Healthcare DENMARK is a public private partnership organization, with a national mandate to promote Danish healthcare solutions and competencies abroad. The partnership is a framework for linking international partners with efficient Danish solutions and does not represent individual companies. He has a solid healthcare background from different executive positions during the latest 20 years. He was CEO of the innovative Danish healthcare-IT company Cetrea, which during 2008- 2012 was established as a leading provider of solutions to the Danish market and during
the same period accessed markets in other Nordic countries, Germany, Netherlands and USA.
Before joining Cetrea, he was responsible for IBM Healthcare and Life Sciences in the Northern and Eastern part of Europe (the countries U.K., Ireland, South Africa, Germany, Austria, Switzerland, the Nordic Countries and Central and Eastern Europe).
Since 2008 he has also been engaged as board member in a number of different healthcare and healthcare-IT companies. During 2012 he was a member of the Danish Governments Growth team for Healthcare and welfare solutions.

Dr. John Rudan

Dr. John Rudan

Professor and Head of Department of Surgery
Britton Smith Chair in Surgery

Dr. Rudan is a Professor and Head of the Department of Surgery at Queen’s University, Kingston Health Sciences Centre. His clinical interest spans across computer-assisted orthopaedic surgery, total joint surgery to oncology. As Director of Clinical Research at the Human Mobility Research Centre (HMRC) and Britton Smith Chair, Dr. Rudan has made significant contributions to patient health and mobility through innovative surgical procedures.
Dr. Rudan is a pioneer in computer-aided research, particularly in Orthopaedics. His effort to integrate this type of surgical platform in the operating theatre has generated over 240 peer-reviewed publications. He also has broad experience in other surgical applications in Neurosurgery, General Surgery and Cardiac Surgery. Currently, in collaboration with the Laboratory for Percutaneous Surgery at Queen’s University, he is leading research in novel navigation for the resection of breast, liver and other soft tissue tumours.
Dr. Rudan is a named inventor on 23 patent applications and 25 patents worldwide, many of which have been licensed to Fortune 500 companies.

Peter Kapitein

Peter Kapitein

Patient Advocate at Inspire2Live

As a Patient Advocate of Inspire2Live Peter connects patients, researchers and clinicians to further research, treatments and care; in the Netherlands as well as international. He organizes congresses, lobbies the matrix of public authorities, health care organizations, insurance companies and health research institutes. Peter also gives lectures and talks to help patients and society to fight cancer where possible and live with cancer with a good quality of life. He writes blogs, articles and books that contribute to these topics. Peter shows people their shining and radiant possibilities in every possible situation and lets them exploit their talents in favour of others. He’s creating Awareness and Hope where hope comes through vision.

Peter is the co-founder of Alpe d’HuZes, the foundation that is most famous for the annual cycling event on Mount Alpe d’Huez and that raised over 125 million euro for the fight against cancer. He works at the Central Bank of the Netherlands as a program manager and advisor for complex and politically difficult problems. His employer facilitates him in this job. Peter was honoured with a doctorate in October 2012 at the Free University in Amsterdam for connecting patients, researchers and clinicians all over the world to contribute to the quality of life of patients and their loved ones.

Dr. Thomas Wilckens

CEO InnVentis Ltd.

Thomas Wilckens is an MD and serial entrepreneur. His current focus is venture InnVentis Ltd (Israel) and the convergence of multi-omics technologies with real-world clinical data and machine learning to enable PRECISION MEDICINE, Thomas is also the founder of the LinkedIn group PRECISION MEDICINE Insight an Associate at deep innovation GmbH, a boutique consultancy headed by the fmr. Head Group R&D Vodafone. Before joining deep innovation, he founded a drug discovery company as CEO/CSO with a focus on inflammatory and metabolic diseases. Thomas obtained his MD at the Ludwig-Maximilian University before heading off to basic research as a scholar of the Max-Planck Society and the Max-Kade Foundation, NY. He held several postdoc positions at leading academic institutions before becoming an entrepreneur. Aside from his work in Precision Medicine he developed a novel concept for value creation in research intensive industries; i.e. “Symbiotic Innovation”. With regard to this project Thomas is an associate at the GLORAD Research Center for Global R&D Management St. Gallen/Shanghai. Thomas is convinced that we will see a disruption of current diagnostics & therapeutic concepts and related business models. This paradigm shift will be induced by the advent of even greater communication and computing capabilities in concert with progress in omics and sensor technologies; i.e. Precision Medicine will ultimately be supported by algorithms for prevention, diagnostics and therapeutic decision making and become available anywhere 24/7.

Yves A. Lussier, MD, FACMI

Yves A. Lussier, MD, FACMI

Associate Vice President for Data Science, The University of Arizona Health Sciences, Director, Center for Biomedical Informatics and Biostatistics

Dr. Lussier is the Associate Vice President for Data Science and Chief Knowledge Officer for The University of Arizona Health Sciences. He also currently serves as the Director of the Center for Biomedical Informatics and Biostatistics, Associate Director for Cancer Informatics and Precision Health, and the Associate Director for Informatics of the BIO5 Institute at The University of Arizona. He is an internationally renowned physician-scientist and a pioneer of the field of translational bioinformatics. A practitioner of medicine for over seventeen years, he has been a member of the administrative board of four hospitals and published over 150 scientific papers and books chapters. He previously served as Director of three NIH-Funded bioinformatics cores at Columbia University and the University of Chicago. Dr. Lussier co-founded Purkinje, the first tablet-based electronic medical records anchored on the first commercial ontology, as well as developed and implemented Vigilens, the first ontology-anchored clinical event monitor that has been in operation at the New York Presbyterian Hospital of Columbia University since 2002. Leveraging bio-ontologies, he has pioneered and enabled clinical interpretation of personal transcriptomes dynamics between two samples, thus abrogating cohort-based statistics requirements

Dr. Lussier strongly believes that since every patient is a unique individual with a wide range of variability in genes, environment, and lifestyle, it is necessary to devise custom strategies when designing treatment methods. In his role as the Director of the Center for Biomedical Informatics and Biostatistics (CB2), he leads the initiative to build a data-driven learning health system, advance precision medicine analytics, and translate Big Data science and genomic discoveries to clinical care for The University of Arizona’s research and clinical communities. In addition to his role with CB2, his research group conducts hypothesis-driven translational research in biomedical informatics using clinical and genomic big data, knowledge technologies, and networks to better understand the pathology, progression, and treatment for diseases at the individual patient level. They are developing scalable computational data science technologies to efficiently and affordably heal humanity – one person at a time.

Lynn G. Dressler, Dr.P.H.

Lynn G. Dressler, Dr.P.H.

Director of Personalized Medicine, Fullerton Genetics Center and Mission SECU Cancer Center, Mission Health.

Dr. Dressler joined Mission Health, in February 2013, to develop and direct the Personalized Medicine and Pharmacogenomics Program. Formerly a faculty member in the Schools of Medicine and Pharmacy at the University of North Carolina at Chapel Hill, and a founding member of the UNC Institute for Pharmacogenomics and Individualized Therapy, Dressler’s 30 year career spans translational laboratory research in cancer, health policy research and the ethical ,legal, and social implications (ELSI) of genomic medicine. Dressler holds a Master’s in Experimental Pathology, a doctorate in Health Policy and completed a fellowship in ELSI research. At UNC, her laboratory conducted the research study that directly led to the FDA approval of the HER2 FISH assay (PathVYsion ™), one of the first pharmacogenomic tests in solid tumors. In North Carolina, nearly 10 years prior to GINA, (Genetic Information Non Discrimination Act, Federal Statute), Dressler worked with the North Carolina General Assembly to pass a law to prohibit discrimination by employers and health insurance providers on the basis of an individual’s genetic information. She has over 100 publications in related fields.

Working closely with NIH/NCI/NHGRI, Dressler has served in many leadership roles (External Advisor to The Cancer Genome Atlas Study (TCGA); NCI caHUB ethics working group, co- Chair Correlative Sciences Committee of the Cancer and Leukemia Group B). She currently serves as a member of the Clinical Pharmacogenomics Implementation Committee (CPIC); an affiliate member of the NIH Consortium IGNITE, and a guest member of the Institute of Medicine’s Roundtable on Translating Genomic Findings to Improve Population Health.

 

Dr. Paul R. Billings

Dr. Paul R. Billings, M.D., Ph.D, FACP, FACMG

Chair, Biological Dynamics, Inc.

Dr. Paul R. Billings is a board-certified internist and clinical geneticist.  He is a Principal in the consultancy, the Bethesda Group and is Chairman of both PlumCare, LLc and Biological Dynamics, Inc.  Dr. Billings has held appointments at Harvard University, UCSF, Stanford University and UCB.  He is a co-founder and CMO of Omicia, Inc.

Atul Butte

Atul Butte, MD, PhD

Director of the Institute of Computational Health Sciences

Atul Butte, MD, PhD is the inaugural Director of the Institute of Computational Health Sciences (ichs.ucsf.edu) at the University of California, San Francisco, and a Distinguished Professor of Pediatrics.  Dr. Butte is also the Executive Director for Clinical Informatics across the six University of California Medical Schools and Medical Centers. Dr. Butte trained in Computer Science at Brown University, worked as a software engineer at Apple and Microsoft, received his MD at Brown University, trained in Pediatrics and Pediatric Endocrinology at Children’s Hospital Boston, then received his PhD from Harvard Medical School and MIT.   Dr. Butte has authored nearly 200 publications, with research repeatedly featured in Wired Magazine, the New York Times, and the Wall Street Journal.  Dr. Butte was elected into the National Academy of Medicine in 2015, and in 2013, he was recognized by the White House as an Open Science Champion of Change for promoting science through publicly available data.  Dr. Butte is also a founder of three investor-backed data-driven companies: Personalis, providing clinical interpretation of whole genome sequences, Carmenta (acquired by Progenity), discovering diagnostics for pregnancy complications, and NuMedii, finding new uses for drugs through open molecular data. Dr. Butte is a principal investigator of three major programs: the California Initiative to Advance Precision Medicine; the California Precision Medicine Consortium, helping recruit tens of thousands of participants into President Obama’s Precision Medicine Initiative; and ImmPort, the clinical and molecular data repository for the National Institute of Allergy and Infectious Diseases.

James N. Czaban

James N. Czaban

Partner & Chairman of the FDA and Medical Products Regulatory Practice Group at DLA Piper LLP

James N. Czaban is a Partner and the Chairman of the FDA and Medical Products Regulatory Practice Group at the international law firm DLA Piper LLP, in Washington, D.C.  In nearly 25 years of private practice, Jim has focused on counseling pharmaceutical, medical device and diagnostic, and other life sciences clients on a broad range of complex regulatory strategies and compliance matters, and regularly represents such clients in legal, public policy, and enforcement matters before the FDA, other administrative agencies, and in the federal courts. Jim has been deeply involved in the law and regulation of Precision Medicine since mapping of the human genome was completed more than 15 years ago. In 2001, Mr. Czaban published one of the first scholarly legal analyses of FDA’s potential approaches to regulating Precision Medicine, titled “Pharmacogenomics: The Uncertain Path to Deciphering the Regulatory Genome,” and more recently, published a comprehensive analysis of FDA’s efforts to tighten its control over the development and commercialization of Precision Medicine technologies, in the article “Promotion of Precision Medicine Under Imprecise Rules” (FDLI 2016).  Mr. Czaban is a recipient of the Burton Award for Legal Excellence (2010) for his groundbreaking work involving FDA regulation of, and patent litigation involving, the emerging field of biosimilar products. He earned his undergraduate degree from the University of California, Berkeley (1988), and his law degree from the University of Virginia School of Law (1992).

Emanuel Petricoin III, PhD

Emanuel Petricoin III, PhD

University Professor, Co-Director Center for Applied Proteomics and Molecular Medicine, George Mason University

Dr. Emanuel F Petricoin has been the Co-Director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University since 2005, where he is a University Professor. Prior to this position, he served as Co-Director of the FDA-NCI Clinical Proteomics Program and a Senior Investigator within the Center for Biologics Evaluation and Research at the FDA from 1993-2005. Dr. Petricoin received his PhD in Microbiology from the University of Maryland in 1990. The focus of the CAPMM is the invention and use of proteomics technologies for personalized therapy, molecular diagnostics and biomarker discovery. He is a co-founder of 4 life science companies, including 2 precision medicine companies: Theranostics Health, Inc. and Perthera, Inc. located in McClean VA, where is a co-founder and Chief Science Officer. He is a co-inventor on 40 filed and published patents, and has authored over 360 peer-reviewed publications and invited reviews. He has authored over 45 book chapters, is a Senior Editor for Cancer Epidemiology Biomarkers and Prevention and on the editorial board of JCO Precision Oncology, Proteomics, Biomedical Microdevices, Proteomics-Clinical Applications, Proteomics-Protocols, Molecular, Carcinogenesis, Journal of Personalized Medicine and Dr. Petricoin is a founding member of the Human Proteomic Organization (HUPO). He has received numerous awards including the University Professorship at George Mason University, the NIH Director’s Award, FDA Distinguished Scientist Award, 2015 Innovator of the Year Award, GAP50 Top Virginia Entrepreneurs, Nifty 50 Award, American Society of Cytopathology Basic Research Award, the Roche Diagnostics/CLAS Distinguished Scientist Award and the Harvard University Leading Edge Award and is s Kentucky Colonel. He is the faculty representative to the George Mason University Research Foundation.

Del E. Webb

Dr. George Poste

Professor of Health Innovation and Chief Scientist, Complex Adaptive Systems Initiative, Arizona State University

Dr. Poste is currently the Professor of Health Innovation and Chief Scientist, Complex Adaptive Systems Initiative, Arizona State University. This program integrates research in genomics, synthetic biology and high performance computing to study the altered regulation of molecular networks in human diseases to develop new diagnostic tests for precision medicine.

He serves on the Board of Directors of Monsanto, Exelixis, Caris Life Sciences and Scientific Advisory Boards at the University of Michigan, Synthetic Genomics and Haplogen GmbH.

He is a Fellow of the U.K. Royal Society, the Royal College of Pathologists and U.K. Academy of Medicine, Member, Council for Foreign Relations, and Institute of Medicine Board on Global Health. He has served as a member of the Defense Science Board of the U.S. Department of Defense and currently serves on advisory committees for several U.S. government agencies in defense, intelligence, national security and healthcare.

Lee S. Schwartzberg

Lee S. Schwartzberg, M.D., F.A.C.P.

Executive Director and Chief Medical Officer, the West Cancer Center

Lee S. Schwartzberg, M.D., F.A.C.P. is the Executive Director and chief medical officer of the West Cancer Center.  He is a Professor of Medicine and Chief, Division of Hematology/Oncology at The University of Tennessee Health Science Center.  Dr. Schwartzberg is board certified in internal medicine, hematology, and medical oncology.   He also serves as President /CMO for Vector Oncology, an oncology specific SMO/CRO.   He was the founding editor-in-chief of the journal Community Oncology and serves as the editor-in-chief of the website Practice Update Oncology.  He serves on the editorial board of the Journal of Supportive Oncology and the ASCO post and is a reviewer for many journals including the New England Journal of Medicine and the Journal of Clinical Oncology.  He also serves on the board of directors for the National Comprehensive Cancer Network.  Dr. Schwartzberg’s major research interests are new therapeutic approaches to breast cancer, targeted therapy and supportive care having published over 150 research papers. He maintains a private practice in medical oncology focusing on breast cancer.

Paul Langley, PhD

Paul Langley, PhD

Adjunct Professor, College of Pharmacy, University of Minnesota, Director, Maimon Research LLC

Dr Langley is a health economist with over 30 years’ experience in consulting, academia and the pharmaceutical industry. The focus of Dr Langley’s academic and consulting activities is on the evidence base to support clinical and formulary decisions. Over the past 15 years Dr Langley has advised health care systems in the US, Australia and the European Union on the need for processes to be put in place to ensure that claims made for products and devices, both clinical and cost-effective, meet the standards of normal science for evaluation and replication. Dr Langley has published widely and at present is directing a program at the University of Minnesota on formulary evaluation with particular emphasis on personalized and precision medicine claims. The critical feature is the presence of an interactive evidence base that supports at risk target populations in the long-term.